Shares of Horizon Pharma (HZNP) were down 33.3% to $10.40 in premarket trading on Monday. The Dublin-based firm reported first-quarter adjusted earnings per diluted share of 21 cents, down 16% from the same period last year, and net sales of $220.9 million, up 8% year-over-year. Analysts had forecast adjusted EPS of 23 cents and revenue of $248.1 million, according to FactSet Research Systems.

For full-year 2017, the company lowered its  net sales guidance range to $1 billion to $1.035 billion from $1.240 billion to $1.290 billion, and its adjusted Ebitda guidance to $315 million to $350 million from $525 million to $575 million.

Also on Monday, Horizon unveiled a deal to buy River Vision Development and its development-stage medicine teprotumumab (RV001), for a $145 million upfront cash payment, plus potential future milestone and earn-out payments. RV001 is a fully human monoclonal antibody being developed for thyroid eye disease.

Meanwhile, shares of OncoMed Pharmaceuticals (OMED) were down 11.4% to $3.20. The Redwood City, Calif.-based firm on Monday reported first-quarter numbers and announced that a phase two study of demcizumab (anti-DLL4, OMP-21M18) in combination with carboplatin and pemetrexed in front-line non-squamous non-small cell lung cancer (NSCLC) did not meet endpoints.

The company reported a first-quarter net loss of $22.6 million compared to $27.2 million in the year-ago period. Revenue was $6.2 million, versus $6.4 million in the first quarter of 2016.

Other biotech movers include Inovio Pharmaceuticals (INO) . The stock was up 7.4% to $6.95 after the company and Regeneron Pharmaceuticals (REGN) signed a clinical study pact for a phase 1b/2a immuno-oncology trial.  Inovio will conduct the study in patients that have newly diagnosed glioblastoma multiforme (GBM). The study will evaluate Regeneron's PD-1 inhibitor, REGN2810, in tandem with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12.

Jim Cramer and the AAP team provide a technical analysis on Allergan AGN. Find out what they are telling their investment club members. Get a free trial subscription to Action Alerts PLUS.

Meanwhile, over on Real Money, John Reese takes a look at five international stocks. Get his insights or analysis with a free trial subscription to Real Money.

More from Health

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

Is CBD Oil Legal? State-By-State and Future Legality

Is CBD Oil Legal? State-By-State and Future Legality

Unilever Taps In-House Executive as CEO

Unilever Taps In-House Executive as CEO

Open Enrollment Means Costly Changes for Some Medicare Advantage Beneficiaries

Open Enrollment Means Costly Changes for Some Medicare Advantage Beneficiaries

How Much Do Doctors Make in 2018?

How Much Do Doctors Make in 2018?